Back |
home / stock / cydy / cydy message board
Subject | By | Source | When |
---|---|---|---|
Makes sense now how Cyrus doesnt last very | justdafactss | investorshub | 04/26/2023 4:59:45 PM |
THE CANCER MARKET SIZE IS GIGANTIC AND LERONLIMAB | Mountainman5 | investorshub | 04/26/2023 4:49:56 PM |
How absurd is the official Cydy and Cyrus | The Dark KnaDDir | investorshub | 04/26/2023 4:06:45 PM |
GOOOOOOOOOOOOOOO CYRUS GOOOOOOOOOOOOOOO $CYDY!!!!!!!!!!!!!!!!!!!!!!!!!!!! | Mountainman5 | investorshub | 04/26/2023 3:55:09 PM |
Looks like the poster will need a second | Grip it and Sip It | investorshub | 04/26/2023 3:49:20 PM |
Im not claiming anything- terrible buy or not. | I_luv_cydy | investorshub | 04/26/2023 3:41:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...